PD-L1 is the primary PD-1 ligand that is up-regulated in solid tumours, where it can inhibit cytokine production and the cytolytic activity of PD-1+, tumour-infiltrating CD4+ and CD8+ T-cells. Here, CD8A is linked to neoplasm.